| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 21.196 | 22.394 | 24.007 | 23.992 | 263.163 | 0 | 0 | 0 | 0 | - |
| Total Income - EUR | 21.207 | 22.394 | 24.007 | 23.992 | 263.486 | 8.024 | 0 | 2.483 | 1.427 | - |
| Total Expenses - EUR | 6.379 | 3.568 | 3.113 | 3.446 | 15.255 | 16.690 | 22.102 | 15.485 | 5.308 | - |
| Gross Profit/Loss - EUR | 14.827 | 18.826 | 20.894 | 20.546 | 248.232 | -8.666 | -22.102 | -13.002 | -3.881 | - |
| Net Profit/Loss - EUR | 14.191 | 18.154 | 20.174 | 19.826 | 245.357 | -8.746 | -22.102 | -13.026 | -3.895 | - |
| Employees | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - |
Check the financial reports for the company - Four Seasons Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 481 | 779 | 1.014 | 1.734 | 1.706 | 925 | 208 | 0 | 456 | - |
| Current Assets | 20.642 | 38.783 | 58.361 | 77.143 | 249.985 | 170.327 | 134.921 | 114.111 | 5.574 | - |
| Inventories | 0 | 0 | 1.442 | 1.416 | 1.388 | 1.362 | 1.332 | 1.336 | 1.332 | - |
| Receivables | 2.527 | 2.678 | 2.719 | 2.784 | 21.653 | 646 | 730 | 1.504 | 1.575 | - |
| Cash | 18.115 | 36.104 | 54.200 | 72.943 | 226.944 | 168.318 | 132.859 | 111.270 | 2.668 | - |
| Shareholders Funds | 19.274 | 37.232 | 56.776 | 75.560 | 245.407 | 169.729 | 133.755 | 113.033 | -3.847 | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | - |
| Debts | 1.849 | 2.330 | 2.599 | 3.317 | 6.284 | 1.523 | 1.374 | 1.078 | 9.877 | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Four Seasons Pharm Srl